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Abstract 
Motivation: Hepatocellular carcinoma (HCC) is a significant health problem worldwide and annual 
number of cases are nearly more than 700,000. However,there are few safe and effective therapeutic 
options for HCC patients.Here, we propose a new approach for predicting therapeutic and aggravating 
drugs for HCCbased ontissue-specificpathways, which considersnot onlyliver tissueand functional in-
formationof pathways, but also the changes of single gene in pathways. 
Results: Firstly, we map genes related to HCC to the liver-specific protein interaction network and get 
anextended tissue-specific gene set of HCC. Then, based on the extended gene set, 12 enriched 
KEGGfunctional pathways are extracted.Using Kolmogorov–Smirnov statistic, we calculate the thera-
peutic scores of drugs based on the 12 tissue-specific pathways. Finally, after filtering by Comparative 
Toxicogenomics Database (CTD) benchmark,we get 3 therapeutic drugs and 3 aggravating drugs for 
HCC. Furthermore, we validate the6potentially related drugs of HCC by analyzingtheiroverlaps with 
drug indications reported in PubMed literatures, and also making CMapprofile similarity analysis and 
KEGG enrichment analysis based on their targets. All analysis results suggest thatour approach is 
effective and accurate for discovering novel therapeutic options for HCC and it can be easily extended 
to other diseases.More importantly, our method can clearly distinguish therapeutic and aggravating 
drugsforHCC, which also can be used to indicateunmarked drug-disease associations in CTD as pos-
itive or negative. 
Contact: lyu@xidian.edu.cn(LY) 
 
 
1 Introduction  
Hepatocellular carcinoma (HCC), also called malignant hepatoma, is a 
major health problem being one of the leading causes of death worldwide 
with annual number of cases exceeding 700,000. It mostly affects patients 
with liver cirrhosis and currently is their most common reason of death. 
However, there are few safe and effective therapeutic options for HCC 
patients. Drug development takes too long and costs too much before tak-
ing new drugs to market (Booth and Zemmel, 2004). By rough estimating, 
it takes about 15 years (DiMasi, 2001) and $800 million to bring a single 
drug to market (Adams and Brantner, 2006). Drug repositioning has been 
used as a profitable and successful strategy for decades to save time and 
money for drug discovery and development. Because the existing drugs 
are usually vetted in terms of safety, dosage and toxicity, they can be ap-
plied in clinical phases more rapidly than newly developed drugs (Ash-
burn and Thor, 2004). Well-known examples include Minoxidil (origi-
nally designed for hypertension; now indicated for hair loss) (Lucky et al., 
2004), Sildenafil (originally designed for pulmonary hypertension; now 
indicated for erectile dysfunction) (Boolell et al., 1996), Amphotericin B 
(originally designed for serious systemic fungal infections; now indicated 
for acute promyelocytic leukemia)(Kleinotiene et al., 2013) and Lipitor 
(originally designed for cardiovascular disease; now indicated for Alzhei-
mer's) (Feldman et al., 2010). 
As the development of technology over the past decade, researchers 
have proposed many computational methods for new drug indications 
through various strategies. Human genetics studies offer the strongest ev-
idence to connect genes to human diseases. Zhang et al. (2016) identified 
22 liver cancer-related enhancer SNPs through integrating GWAS data 
and histone modification ChIP-seq data in 2016. Sanseau et al. (2012) 
found that disease genes extracted from GWAS data were enriched 2.7-
fold in drug targets. Besides, they uncovered 123 drug targets which were 
associated with GWAS traits when not to consider their original indica-
tions. These mismatches opened the door for drug repositioning. Bamshad 
et al. (2011) dissected the genetic basis of diseases and traits by exon se-
quencing which is the targeted sequencing of the subset of the human ge-
nome that encodes proteins. Their strategies have focused on identifying 
individual genes that exhibit differences between normal and disease 
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states. In fact, genes within a cell do not function alone. They interact with 
each other to carry out specific biological functions. Complex diseases are 
generally caused by the dysregulation of a set of genes that share common 
biological function. 
Some pathway-based computational approaches were proposed re-
cently to overcome this problem. Ye et al. (2012) integrated known drug 
target information and proposed a disease-oriented strategy for evaluating 
the relationship between drugs and disease based on their pathway profiles. 
Pathway profile is a vector with 185 dimensions and each element in the 
vector is a p-value of the hypergeometric test corresponding to 185 KEGG 
pathways (Kanehisa et al., 2010). In the next year, Li and Lu (2013) con-
structed a multi-layer causal network (CauseNet) consisting of chains 
from drug to target, target to pathway, pathway to downstream gene, and 
gene to disease. The transition likelihood of each causal chain in the net-
work was measured by a statistical method based on known drug-disease 
treatment relationships. Zhao et al.(2013) extended the concept of cancer 
signaling bridges (CSB) and developed a computational model to derive 
specific downstream signaling pathways that revealed previously un-
known target-disease connections and new mechanisms for specific can-
cer subtypes. Pathway analysis can effectively uncover the perturbation of 
biological systems by diseases. However, a common problem of these 
methods is that they treat pathways simply as gene sets and ignore the 
changes of single gene in pathways and tissue-specific information of 
pathways. Moreover, these methods cannot clearly distinguish therapeutic 
and aggravating drugs for diseases. 
In this study, we propose an approach to identify related drugs for treat-
ments of HCC, which considers the functional information of pathways, 
the changes of single gene in pathways and the special relationship be-
tween HCC and liver tissue. More importantly, our method can clearly 
distinguish the potential drugs are therapeutic or aggravating for HCC, 
which can be used to indicate unmarked drug-disease associations in CTD 
as positive or negative. Fig 1 gives the flowchart of our proposed method. 
First, we map all the genes related to HCC to the tissue-specific protein 
interaction network of liver and get an extended tissue-specific gene set of 
HCC. Then, based on the extended gene set, we extract 12 liver-specific 
pathways by KEGG pathway enrichment analysis. Using Kolmogorov–
Smirnov statistic (Hollander et al., 2013 ), we calculate the therapeutic 
scores of drugs based on the 12 pathways. Finally, after filtering by Com-
parative Toxicogenomics Database (CTD) benchmark (Davis et al., 2015), 
we get top-6 potential drugs according to their scores, in which 3 drugs 
have the probability to treat HCC and the other three drugs may aggravate 
HCC. We validate the 6 predicted drugs by analyzing their overlaps with 
drug indications reported in PubMed literatures. In addition, we also make 
Connectivity Map (CMap)(Lamb et al., 2006) profiles similarity analysis 
and KEGG enrichment analysis on their related genes. All these findings 
suggest that our approach is effective for accurate discovering novel ther-
apeutic options for HCC and easily to be extended to other diseases. 
 
Fig 1.The framework of our method to predict related drugs for HCC. 
(1) We compare control samples with tumor samples by Limma to generate a list of up-
regulated and down-regulated genes for HCC disease. Genes are ranked by their expression 
values. The red circles represent up-regulated genes, while the blue circles represent down-
regulated genes. (2) We integrate disease related genes and liver tissue-specific network to 
construct a tissue-specific genes signature of HCC. Based on the tissue-specific gene sets, 
we extract 12 related pathways by KEGG pathway enrichment analysis. The purple circles 
represent the related genes of HCC, the other green circles represent other genes in the 
network. (3) Genes in each pathway are ranked based on their expressions obtained from 
(1). (4) 6100 gene expression instances of drugs from the Connectivity Map. (5) Different 
orders of the same gene in pathway ( 1,2,...,12)iP i   and instance ( 1,2,...,6100)jI j  . 
Based on the different orders of genes in pathway ( 1,2,...,12)iP i  and instance
( 1,2,...,6100)jI j  , we calculate the therapeutic score of each drug using Kolmogorov-
Smirnov statistic. (6) Drugs are ranked according to their therapeutic scores. The orange 
bars (therapeutic scores < 0) represent the therapeutic drugs and the green bars (therapeutic 
scores > 0) represent the aggravating drugs.  
2 Methods 
2.1 Extract tissue-specific subnetwork of HCC.  
HCC is a cancer that starts in the liver. In order to obtain the tissue-specific 
subnetwork of HCC, we first get nine related genes of HCC from Online 
Mendelian Inheritance in Man (OMIM) (Hamosh et al., 2005) , shown in 
Table 1. OMIM is a comprehensive, authoritative compendium of human 
genes and genetic disorders to support research and education in human 
genomics and the practice of clinical genetics. Then, the nine genes related 
to HCC are extended through obtaining the direct neighbors of nine genes 
in liver-specific protein-protein interaction (PPI) network got from 
GIANT(Greene et al., 2015). GIANT is a dynamic, interactive web inter-
face of tissue-specific networks. Finally, we obtain a subnetwork from the 
liver PPI network, which contains 58 genes and 838 edges with 
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0.1weight  (S2 Table). This subnetwork has high average clustering co-
efficient and node degree, and small average shortest path length. The de-
tail information is shown in Table 2. That is to say, the subnetwork has a 
considerable density and the correlations between 9 HCC genes with other 
genes are very strong. Hence, we take the 58 genes in the subnetwork as 
the new gene set related to HCC. 
Table 1. HCC related genes extracted from OMIM 
Gene Names Gene Entrez IDs 
IGF2R 3482 
CASP8 841 
MET 4233 
PDGFRL 5157 
TP53 7157 
PIK3CA 5290 
LCO 3935 
CTNNB1 1499 
AXIN1 8312 
Table 2. Network topological attributes of the tissue-specific sub-net-
work of HCC 
Attribute names Values 
Number of nodes 58 
Number of edges 838 
Average node degree 28.9 
Average clustering coefficient 0.69 
Average the shortest path length 1.5 
Maximal diameter 3 
2.2 Construct HCC tissue-specific pathway signatures. 
Because HCC is a complex disease and complex diseases generally in-
volve several gene mutations and pathway dysregulations (Chen et al., 
2009; Chen et al., 2010), we further analyze the biological functions of 58 
genes got from the tissue-specific PPI network of HCC. By using DAVID 
tool (Huang et al., 2009), we perform pathway enrichment analysis on 
these genes. The parameters of DAVID are set as: p-value = 0.001 and 
count = 5. Finally, we obtain 12 KEGG pathways (Kanehisa et al., 2010) 
related to the 58 genes (see Table 3). There are totally 28 of 58 (48.3%) 
tissue-specific genes are enriched in these 12 KEGG pathways. Therefore, 
we name the 12 KEGG pathways as HCC-specific pathways (shown in 
Fig 1(2)).    
Through analyzing the gene expression data of HCC (see section “Da-
tasets”), we can get a ranked gene list of HCC based on their expression 
values. The genes in the list are divided into two sets: the up-regulated set 
and the down-regulated set (shown in Fig 1(1)). We compare control sam-
ples with tumor samples by Limma (Smyth, 2004) to generate a list of up-
regulated and down-regulated genes for HCC disease. Genes are ranked 
by logFC , actually     2logFC=log mean tumor /mean control , where 
 mean tumor and  conmean trol  represent the average of the expres-
sion value of a gene across all tumor samples and all control samples re-
spectively. If the logFC  of a gene is greater than zero, then the gene is 
up-regulated, otherwise the gene is down-regulated. Then, based on the 
ranked gene list, we rank the genes in each HCC-specific pathway (shown 
in Fig 1 (3)). In this way, we obtain 12 ranked HCC-specific gene lists, 
which are named as HCC tissue-specific pathway signatures (S3 Table3). 
Table 3. Twelve enriched KEGG pathways with HCC 
Pathways Number of HCC-specific genes P-values
Pathways in cancer 20 3.06E-13
Prostate cancer 10 1.41E-08
Adherens junction 8 1.44E-06
Endometrial cancer 7 2.15E-06
Colorectal cancer 8 2.62E-06
Apoptosis 8 3.32E-06
Melanoma 7 1.36E-05
Wnt signaling path-
way 9 1.41E-05
Cell cycle 7 3.28E-04
Notch signaling path-
way 5 4.16E-04
Basal cell carcinoma 5 7.61E-04
Melanogenesis 6 8.61E-04
2.3 Calculate the therapeutic scores of drugs.  
We get 6100 gene expression instances covered 1,309 drugs from Cmap 
database. In other words, a drug may correspond to multiple instances. We 
rank the genes in each instance by taking the differential expression values 
between drug-treated and drug-untreated cell lines (shown in Fig 1(4)). 
Finally, we get 6100 drug-related gene lists. If the gene expression profiles 
related to a drug positively correlate to that of HCC-specific pathways, the 
drug may worsen HCC. On the contrary, if their relationship is negative, 
the drug may treat HCC. The reason is that the positive correlations show 
that drugs may strengthen the expressions of disease genes and the nega-
tive correlations represent that the drugs may inhibit the expressions of 
disease genes. Therefore, based on 12 HCC-specific pathways and 6100 
drug-related gene expression instances, we use a nonparametric, rank-
based pattern matching strategy originally introduced by Lamb et al. (2006) 
to evaluate the relationship between drugs and HCC (shown in Fig 1 (5)).   
We take each ranked drug expression profile as reference signature and 
assess their similarity to each HCC pathway. For a HCC pathway i  and a 
drug expression profile j , we compute a connectivity score separately for 
the set of up- or down-regulated genes in the pathway i : ,i jupCS  or ,downi jCS . 
For the HCC pathway i , it needs up- ( upG ) or down-regulated genes 
( downG ) as inputs. The computational formulas as follows (Lamb et al., 
2006): 
                                       1
m
p
V ppa Max
m n
                                       (1) 
                                      1 1
m
p
V p pb Max
n m
                                      (2) 
                                         (if a b)(if a b)
a
CS
b
      
                                    (3) 
Where n  represents the total number of genes in the reference drug 
expression profile j ; m  represents the number of up-regulated genes 
upG , or the number of down-regulated genes downG ; p represents the po-
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sition of the input set ( 1...p m ); ( )V p  is the position of the thp  in-
put gene in the gene list of drug expression profile j ; CS  represents the 
connectivity score ,i jupCS  or ,downi jCS  for the up- or down-regulated gene set. 
The therapeutic score ( TS ) between a drug with k  instances in CMap 
and HCC with 12 functional pathways is calculated as follows: 
                                          
12 ,
1 1
1 k i j
i j
TS CS
k  
                                     (4) 
where the drug has k  instances in CMap and HCC has 12 functional path-
ways; ,i jCS  represents the connectivity score between HCC pathway i  
and instance j , which is defined as: 
                                         , , ,i j i j i jup downCS CS CS                                   (5) 
where ,i jupCS  and ,i jdownCS  represent the connectivity scores for the up-
regulated gene set and the down-regulated gene of pathway i  respectively, 
and their definitions are given in formula (3) to (5). 
If the up-regulated pathway genes are near the top (up-regulated) of 
the rank-ordered drug gene lists and the down-regulated pathway genes 
are near the bottom (down-regulated) of the rank-ordered drug gene lists, 
we can get high positive therapeutic scores (TS), which indicate the drugs 
and the HCC pathways have similar expression profiles and the drugs 
might aggravate HCC. On the other hand, if the up-regulated pathway 
genes are near the bottom of the rank-ordered drug gene lists and the 
down-regulated pathway genes are near the top of the rank-ordered drug 
gene lists, we can get negative therapeutic scores(TS), which imply the 
given drugs and the HCC pathways have adverse expression profiles and 
the drugs could be treatment candidates for HCC. Both cases are signifi-
cant for HCC treatment. 
2.4 Datasets 
HCC gene expression data. We download the gene expression profiles of 
HCC from the NCBI Gene Expression Omnibus (GEO)(Edgar et al., 
2002). The gene expression dataset (GSE45436) contains 134 samples, 
including 95 tumor samples and 39 control samples. Each probe is mapped 
to a gene using GPL570 platform obtained from GEO, while the probes 
are removed if they do not match any gene. If multiple microarray probes 
are mapped to a same gene, we assign the average of expression values to 
the gene.  
Here, the expression values of all genes are standardized as follows:  
                                  ( )( )
ij i
ij
i
g mean g
z
std g
                                       (6)  
where ijg represents the expression value of gene i in sample j , and 
 imean g and  istd g respectively represent mean and standard devia-
tion of the expression vector for gene i  across all samples. 
Gene expression data related to drugs. The gene expression data related 
to drugs is downloaded from the CMap database (Lamb et al., 2006). It 
contains 6,100 instances, which cover 1,309 drugs. These instances are 
measured on five types of human cancer cell lines, including the breast 
cancer epithelial cell lines MCF7 and ssMCF7, the prostate cancer epithe-
lial cell line PC3, the nonepithelial lines HL60 (leukemia) and SKMEL5 
(melanoma). 
 
3 Results 
3.1 Choose Potential HCC Drugs through CTD Benchmark 
The quick brown fox jumps over the lazy dog. The quick brown fox jumps 
over the lazy dog. The quick brown fox jumps over the lazy dog. The quick 
brown fox jumps over the lazy dog. The quick brown fox jumps over the 
lazy dog. The quick brown fox jumps over the lazy dog. The quick brown 
fox jumps over the lazy dog. The quick brown fox jumps over the lazy 
dog. The quick brown fox jumps over the lazy dog. The quick brown fox 
jumps over the lazy dog. The quick brown fox jumps over the lazy dog. 
The quick brown fox jumps over the lazy dog.  
To find most likely HCC-related drugs, we need evaluate the precision of 
our method firstly. We take CTD (Davis et al., 2015) as benchmark. CTD 
provides manually curated information about drug-gene interactions, 
drug-disease and gene-disease relationships. Curated chemical-disease as-
sociations are extracted from the published literature by CTD biocurators 
and inferred associations are established via CTD curated chemical-gene 
interactions.  
For a drug in CMap, if it cannot find corresponding chemical name in 
CTD, we will not calculate its therapeutic score (defined in section “Meth-
ods”). In this way, we finally get 1168 scored drugs. Because most drug-
disease associations in CTD are not marked as positive or negative, we 
rank the 1168 drugs in descending order by the absolute values of their 
therapeutic scores (S1 Table). We know the top drugs imply stronger con-
nections with HCC. And then we calculate the precisions of our approach 
at different top-x drugs, which are shown in Fig 2. The precision is calcu-
lated as follows:  
                                             CTDPprecision
P
                                    (7) 
where P represents the number of top-x drugs; PCTD represents the number 
of drugs in the top-x drugs can be found related with HCC in CTD data-
base. 
 
Fig 2. The precision of our approach at different top-x drugs. 
We find in the top-10 drugs (x=10), there are 9 drugs associated with 
HCC in CTD. That is to say, the precision is 0.9. For the top-20 drugs 
(x=20), the precision is 0.85 and there are three potentially HCC-related 
drugs. When x is 30, its precision is 0.8 and we get six potential drugs with 
HCC. From the Fig 2, we notice that with the increase of x, the precision 
declines and the number of potential drugs increases. We hope we can 
predict relatively more HCC-related drugs with high precision. Therefore, 
we choose top-30 (x = 30) drugs for further analysis. 
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3.2 Validate potentially HCC-related Drugs through Pub-
Med Literature 
In the above section, we choose the top-30 drugs (precision = 0.8) for fur-
ther analysis. There are 12 therapeutic drugs with negative TS values in 
the top-30 drugs, shown in Table 4. Nine of them can be found having 
connections with HCC in CTD. But only one of the 9 drugs is marked as 
therapeutic drug (Rank=3 and Evidence = "T" in Table 4) for HCC and 
the other 8 inferred drugs are unmarked in CTD. Here, we can indicate 
these 8 unmarked drugs are possibly therapeutic drugs for HCC. The rest 
three drugs (Securinine, Isocarboxazid and Ajmaline) are newly predicted 
ones by our method, which are marked as bold in Table 4. Based on Pub-
Med, we analyze the three drugs further. PubMed (pubmed.gov) is a free 
resource developed and maintained by the National Center for Biotech-
nology Information (NCBI) at the National Library of Medicine (NLM). 
PubMed comprises more than 26 million references and abstracts on life 
sciences and biomedical topics.  
Table 4. Twelve Therapeutic Drugs for HCC in the Top-30 Drugs. 
Rank Drug Name Evidence Ref Count
1 Geldanamycin inferred 33 
2 Lomustine inferred 1 
3 Securinine NULL NULL 
4 Clozapine inferred 35 
5 Suramin inferred 14 
6 Rosiglitazone inferred 79 
7 Furazolidone inferred 7 
8 Hydrocortisone inferred 30 
9 Isocarboxazid NULL NULL 
10 Ajmaline NULL NULL 
11 
1-(5-Isoquinolinesul-
fonyl)-2-Methylpiper-
azine 
inferred 15 
12 Troglitazone T 86 
Evidence represents a drug-disease association is curated, inferred or 
not existed in CTD database. Curated associations include three types: 
marker/mechanism (Evidence = "M"), therapeutic (Evidence = "T"), 
marker/mechanism & therapeutic (Evidence = "M&T"). If an association 
is inferred by CTD, Evidence = "inferred", and if it is not existed in CTD, 
Evidence = "NULL"; Ref Count represents the number of reference (s) for 
the curated and inferred associations. If an association is not existed in 
CTD, Ref Count = "NULL". 
Securinine (Rank=3 in Table 4), a quinolizine pseudoalkaloid (not from 
amino acid) from securinega suffurutiosa or securinini nitras, is one of 
central nervous stimulants and clinically applied to treat amyotrophic lat-
eral sclerosis (ALS), poliomyelitis and multiple sclerosis (Buravtseva, 
1958; Copperman et al., 1973; Copperman et al. 1974). It has been found 
to be active as a γ-amino butyric acid (GABA) receptor antagonist (Beut-
ler et al., 1985). GABA is the chief inhibitory neurotransmitter in the cen-
tral nervous system and plays a principal role in reducing neuronal excit-
ability throughout the nervous system. Studies show that GABA stimu-
lates HCC cell line HepG2 growth (Li et al. 2012). Consequently, it means 
that securinine is a promising agent with therapeutic potential for HCC 
through inhibiting GABA receptor. The mechanism is depicted in Fig 3A. 
 
Fig 3. Description of the mechanism of drugs and HCC. A. The mecha-
nism of securinine treating HCC. Securinine has been found to be active as a γ-amino bu-
tyric acid (GABA) receptor antagonist. GABA stimulates HCC cell line HepG2 growth. 
Consequently, it means that securinine is a promising agent with therapeutic effect on HCC 
patients through inhibiting GABA receptor. B. The mechanism of ethisterone aggravating 
HCC. Ethisterone is a synthesized progestin and it can increase the expression of vascular 
permeability factor (VEGF). The overexpression of VEGF can contribute to the prolifera-
tion of HCC tumor cells. Hence ethisterone gets aggravating effect on HCC patients 
through increasing the expression level of VEGF.  
Isocarboxazid (Rank=9 in Table 4) is a non-selective, irreversible mon-
oamine oxidase inhibitor (MAOI) used as an antidepressant (Fagervall et 
al., 1986). It has been investigated in the treatment of Parkinson's disease 
and other dementia-related disorders. MAOIs inhibit the activity of the 
monoamine oxidase enzyme family and decrease dopamine production 
(Goldstein et al., 2016). Dopamine is an organic chemical belong to cate-
cholamine and phenethylamine families and plays several important roles 
in the brain and body. It is synthesized from L-DOPA, which is produced 
in the brain and kidneys. Studies have revealed that dopamine receptors 
(DRs) are over expressed in the HCC (Villa et al., 2005; Lu et al., 2015), 
and the overexpression of DRs improves the chance combining with do-
pamine. However, isocarboxazid can decrease this chance by reducing do-
pamine. Therefore, isocarboxazid has the potential role in the treatment of 
HCC.  
Ajmaline (Rank=10 in Table 4) is a sodium ion channel blocker. It has 
served as a treatment for Wolff-Parkinson-White syndrome (WPW) which 
is a disorder of the electrical system of the heart referred to arrhythmia 
with the ventricles contracting prematurely. Sodium channel blockers are 
drugs which impair conduction of sodium ions (Na+) through sodium 
channels. The sustained low extracellular sodium ion concentration de-
crease glutamate uptake (Fujisawa et al., 2015). Glutamine is an essential 
compound in cellular metabolism and a fuel for cell proliferation, so the 
decrease of glutamine will inhibit tumor proliferation (Hensley et al., 
K.Takahashi et al. 
 
2013). Hence, ajmaline provides an accessible therapeutic window for 
HCC treatment. 
The other 18 drugs with negative TS values are shown in Table 5. They 
are possible to aggravate HCC. 15 of them have been found having rela-
tionships with HCC in CTD database and we can infer these relationships 
are possibly negative. The remaining 3 drugs (Pridinol, Piperacillin and 
Ethisterone) are newly potential drugs for aggravating HCC marked as 
bold in Table 5. We will investigate the three drugs (Pridinol, Piperacillin 
and Ethisterone) based on PubMed. 
Pridinol (Rank=7 in Table 5) is a muscle relaxant that is able to alleviate 
pain (Merck, 1989). In PubMed, there are only eight articles related to 
pridinol. Due to lack of information about pridinol, it is hard for us to find 
evidences to infer that pridinol may aggravate HCC. We are confident that 
our prediction for pridinol aggravating HCC will be verified in the future. 
Piperacillin (Rank=9 in Table 5) is a well-known β-lactam antibiotic 
(Holten, 2000). β-lactam antibiotics work by inhibiting the biosynthesis of 
the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is 
the outermost and fundamental component of cell walls, and it is crucial 
for cell wall structural integrity. Blocking the synthesis of the peptidogly-
can layer destroys the bacterial cell wall and induces bacterial cell rupture. 
Lipopolysaccharides (LPS) are released because of bacterial cell rupture 
(Parija, 2014). Studies demonstrate that LPS promotes proliferation, ad-
hesion and invasion of hepatoma cells (Liu et al., 2014). Therefore, pipe-
racillin probably aggravates HCC indirectly by distracting the bacterial 
cell wall. 
Ethisterone (Rank=13 in Table 5) is a synthesized progestin. Studies 
revealed that natural and synthetic progestin increased the expression of 
vascular permeability factor(VEGF). VEGF is a signal protein involved in 
vasculogenesis and angiogenesis and its principal function is to produce 
new blood vessels during embryonic development after blood vessels in-
jury. VEGF also is a potent angiogenesis growth factor. The overexpres-
sion of VEGF and its receptors has been associated with poor prognosis 
in HCC (Dhar et al., 2001;  Tseng et al., 2008). Moreover, the overexpres-
sion of VEGF can contribute to the proliferation of HCC tumor cells. If 
HCC patients orally take ethisterone, the level of VEGF will increase. The 
situation of those patients will be more terrible. Hence, ethisterone gets 
some evil influence over HCC patients (The mechanism depicts in Fig 3B). 
Table 5. Eighteen Aggravating Drugs for HCC in the Top-30 Drugs. 
Rank Drug Name Evidence References_count 
1 Scriptaid inferred 7 
2 Entinostat inferred 37 
3 Trichostatin A inferred 89 
4 Harman inferred 1 
5 Estradiol inferred 116 
6 Riboflavin inferred 18 
7 Pridinol NULL NULL 
8 Diethylstilbestrol inferred 69 
9 Piperacillin NULL NULL 
10 Nilutamide inferred 2 
11 
N-(2-cyclohexyloxy-
4-nitrophenyl)-me-
thanesulfonamide 
inferred 32 
12 Trioxsalen inferred 1 
13 Ethisterone NULL NULL 
14 Fulvestrant inferred 59 
15 Acacetin inferred 1 
16 Cetirizine inferred 2 
17 Dinoprost inferred 18 
18 Haloperidol inferred 33 
Evidence represents a drug-disease association is curated, inferred or not existed in CTD 
database. Curated associations include three types: marker/mechanism (Evidence = "M"), 
therapeutic (Evidence = "T"), marker/mechanism & therapeutic (Evidence = "M&T"). If 
an association is inferred by CTD, Evidence = "inferred", and if it is not existed in CTD, 
Evidence = "NULL"; Ref Count represents the number of reference (s) for the curated and 
inferred associations. If an association is not existed in CTD, Ref Count = "NULL". 
3.3 Analyze potentially HCC-related Drugs through CMap 
database 
The CMap database can not only be applied to calculate drug-disease cor-
relations, but also can be used to identify connections between two drugs. 
In particular, for a same disease, if two drugs have strongly positive rela-
tionship, they may have similar effects on this disease. On the contrary, if 
their relationship is negative, they may have opposite effects. In this sec-
tion, we further analyze the six predicted drugs (three therapeutic drugs 
shown in Table 4: Securinine, Isocarboxazid and Ajmaline; three aggra-
vating drugs shown in Table 5: Pridinol, Piperacillin and Ethisterone) 
based on CMap and estimate their correlations (evaluated by formula (5)) 
with known HCC drugs marked as “therapeutic” in CTD database. The 
results are shown in Table 6. 
For the three potentially therapeutic drugs (Securinine, Isocarboxazid 
and Ajmaline) marked as bold in Table 6, we find that securinine yields 
highly positive connectivity score (calculated by formula (5)) for dauno-
rubicin, troglitazone and paclitaxel. Daunorubicin is a chemotherapy med-
ication used to treat cancer. The liposomal formulation of the anthracy-
cline daunorubicin has low systemic toxicity and is taken up strongly by 
the liver. The researchers found that daunorubicin was an active agent 
against HCC (Daniele et al., 1999). Troglitazone is a thiazolidinedione 
PPARγ agonist that exhibits anti-diabetic, anticancer, anti-fibrotic, and 
anti-inflammatory activities. Studies (Yu et al., 2006) found a significant 
decrease in expression of PPARγ mRNA and protein in human liver can-
cers compared with surrounding nontumorous liver. Troglitazone induces 
PPARγ expression and inhibits cell growth both in vitro and in vivo  (Yu 
et al., 2006). Paclitaxel is a cancer medication that interferes with the 
growth and spread of cancer cells in the body (Huang et al., 2015). Studies 
indicate that paclitaxel is cytotoxic to cultured hepatocellular carcinoma 
cells (Gagandeep et al., 1999) and is a common chemodrug for therapy of 
HCC patients (Yan et al., 2013; Chen et al., 2015;  Chao et al., 1998). 
Isocarboxazid is found having strongly positive relationships with dox-
orubicin, sirolimus and troglitazone. Doxorubicin has been regarded as 
one of the effective chemotherapy medication used to treat cancer  (Weiss, 
1992). One way that doxorubicin works is by blocking an enzyme called 
topo isomerase 2 that cancer cells need to divide and grow. Sorafenib, a 
multikinase inhibitor, has been shown to be effective and safe monother-
apy in patients with advanced HCC. A recent phase II study revealed the 
safety and efficacy of the combined use of sorafenib and doxorubicin-
TACE in patients from the Asia-Pacific region with intermediate HCC 
(Chung et al., 2013). The disease control rate and overall response rate 
were reported to be 91.2% and 52.4%, respectively. Also, doxorubicin is 
used to improve the survival rate of unresectable HCC patients (Shang et 
al., 2016). Sirolimus is a macrolide compound and is indicated for the pre-
vention of organ transplant rejection. The data suggested a beneficial ef-
fect of sirolimus immunosuppression on the recurrence of hepatocellular 
carcinoma after liver transplantation (Hanish and Knechtle, 2011; Chin-
nakotla et al., 2009). Moreover, researchers found sirolimus could inhibit 
the growth of human hepatoma cells (Schumacher et al., 2002). 
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Ajmaline gets high positive connectivity scores with nimesulide, dexa-
methasone, doxorubicin and paclitaxel. Nimesulide is a cyclooxygenase-
2 (COX-2) inhibitor and is used to inhibit the proliferation and promote 
apoptosis of Hep G2 (a human liver cancer cell line) by up-regulating 
Smad4 (Yang et al., 2012). Dexamethasone, a type of corticosteroid med-
ication, can restore gluconeogenesis in malignant hepatocytes by bypass-
ing the abnormal regulation of 11β-HSD enzymes, which indicates that 
targeting altered metabolism in liver cancer could prove useful as a thera-
peutic strategy for HCC (Ma et al., 2013). 
For the three potentially aggravating drugs (Pridinol, Piperacillin and 
Ethisterone) in Table 3, they all have negative relationship with known 
HCC drugs. Pridinol has high negative connectivity scores with genistein, 
nimesulide, troglitazone and sirolimus. Piperacillin have clear negative 
connection scores with dexamethasone, genistein, paclitaxel and sirolimus. 
Ethisterone have clear negative connection scores with dexamethasone, 
genistein, sirolimus and troglitazone. Genistein is one of the most abun-
dant isoflavones in soy that is described as an angiogenesis inhibitor and 
a phytoestrogen (Walter, 1941). Researcher found genistein and its inhi-
bition of multiple signal transduction pathways could control the invasive-
ness and metastatic potential of HCC (Wang et al., 2014) and the combi-
nation of ATO with genistein would present a promising therapeutic ap-
proach for the treatment of HCC (Ma et al., 2011). More details about the 
other known HCC drugs have been introduced in the above sections.  
Table 6. The relationships of six predicted drugs with known HCC thera-
peutic drugs in CTD. 
Predicted 
Drugs 
Known HCC Drugs in 
CTD 
Connectivity 
Scores 
Securinine 
Daunorubicin 0.397 
Troglitazone 0.504 
Paclitaxel 0.321 
Isocarboxazid 
Doxorubicin 0.31 
Sirolimus 0.432 
Troglitazone 0.436 
Ajmaline 
Nimesulide 0.542 
Dexamethasone 0.41 
Doxorubicin 0.36 
Paclitaxel 0.424 
Pridinol 
Genistein -0.377 
Nimesulide -0.269 
Troglitazone -0.442 
Sirolimus -0.382 
Piperacillin 
Dexamethasone -0.436 
Genistein -0.336 
Paclitaxel -0.299 
Sirolimus -0.408 
Ethisterone 
Dexamethasone -0.369 
Genistein -0.223 
Sirolimus -0.236 
Troglitazone -0.267 
The potentially therapeutic drugs of HCC are marked as bold. The other three drugs are 
potentially aggravating drugs of HCC. 
 
All in all, these results indicate that our method can find both therapeu-
tic drugs and aggravating drugs for diseases. Moreover, our method can 
be applied to mark the known drug-disease associations as positive or neg-
ative, such as some drug-disease associations in CTD database, to provide 
a better basis for the treatment of diseases.  
3.4 Pathway Enrichment Analysis 
Furthermore, we try to apply DAVID functional annotation tool (Huang 
et al., 2009) to identify enriched KEGG pathways of the above six drugs 
based on their targets. If the targets of a drug have close correlations with 
HCC-related pathways, it is very likely that the drug is helpful for the 
treatment of HCC. The pathway details are shown in Table 7. Because 
securinine, pridinol and ethisterone have no target information at present 
in DrugBank, they have no related KEGG pathways.  
The potentially therapeutic drugs of HCC are marked as bold. The other 
three drugs are potentially aggravating drugs of HCC. “NULL” represents 
the drug has no targets in DrugBank at present. Thus, its corresponding 
KEGG pathway is “NULL” too. 
Isocarboxazid has two targets “MAOA and MAOB” and they relate 
with 13 KEGG pathways. Some of them have been reported having close 
relationships with liver cirrhosis or HCC. For example, for the alcoholism 
pathway, the researchers found chronic alcohol consumption had long 
been associated with progressive liver disease toward the development of 
hepatic cirrhosis and the subsequent increased risk for developing HCC 
(McKillop and Schrum, 2009). Metabolic pathways are linked series of 
chemical reactions occurring within a cell. The results showed that the 
metabolism in the HCC tumor was modified to promote cellular prolifer-
ation or escape from apoptosis (Huang et al., 2013). For the drug metabo-
lism-cytochrome P450 pathway, cytochrome P450 1A1 is a major enzyme 
in the bioactivation of exogenous procarcinogens of hepatocellular carci-
noma (HCC) (Li et al., 2009). For the drug ajmaline, it has one enriched 
pathway, adrenergic signaling in cardiomyocytes. The adrenergic signal-
ing pathway plays an important role in cancer progression by regulating 
multiple cellular processes (Cole and Sood, 2012; Fitzgerald, 2012; Fitz-
gerald, 2009). 
Table 7. Pathway enrichment analysis result of six selected drugs. 
Drug Name Drug Targets KEGG Pathways 
Securinine NULL NULL 
Isocarboxa-
zid 
MAOA, 
MAOB 
Phenylalanine metabolism; 
Histidine metabolism; 
Tyrosine metabolism; Glycine, 
serine and threonine metabo-
lism; Tryptophan metabolism; 
Cocaine addiction; Arginine 
and proline metabolism; Am-
phetamine addiction; Drug me-
tabolism - cytochrome P450; 
Serotonergic synapse; Dopa-
minergic synapse; Alcoholism; 
Metabolic pathways 
Ajmaline SCN5A Adrenergic signaling in cardio-myocytes 
Pridinol NULL NULL 
Piperacillin PBP3, PENA, PBP2A, PBP1B Peptidoglycan biosynthesis 
Ethisterone NULL NULL 
There are nine of thirteen pathways in which isocarboxazid drug targets 
exist and these nine pathways have common genes with the 12 tissue-spe-
cific KEGG pathway of HCC (Table 3). The interaction between the nine 
pathways and the 12 tissue-specific KEGG pathway of HCC is shown in 
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Fig.4. Tyrosine metabolism has common genes with one pathways which 
are tissue-specific KEGG pathway of HCC. There are common genes be-
tween Cocaine addiction and seven  HCC related pathways. For Arginine 
and proline metabolism, it exits common genes with one HCC related 
pathway. There are common genes between Amphetamine addiction and 
seven HCC related pathways. Drug metabolism-cytochrome P450 has 
common genes with two HCC pathways. Serotonergic synapse has com-
mon genes with ten pathways of liver cancer. Dopaminergic synapse has 
common genes with nine pathways of liver cancer. There are common 
genes between Alcoholism and five HCC related pathways. For Metabolic 
pathways, it exits common genes with seven HCC related pathway. 
 
Figure 4. .Pathway analysis of isocarboxazid drug targets. The purple 
circle represents pathways of the mercaptopurine drug targets appeared, 
and the green circle represents tissue-specific KEGG pathway of HCC. 
The gray side indicates that there is a common gene between two pathways, 
and the more number of public genes is, the more rough edge is. 
There is only one pathway in which Ajmaline drug targets exist. How-
ever, Adrenergic signaling in cardiomyocytes has common genes with ten 
of 12 tissue-specific KEGG pathway of HCC (Table 3). The interaction 
between the six pathways and the 12 tissue-specific KEGG pathways of 
HCC is shown in Fig.5.  
These results further show that these potential drugs have close rela-
tionships with HCC. With the improvement of data, our algorithm will 
perform better.   
 
Figure 5. Pathway analysis of reserpine drug targets. The purple circle 
represents pathways of the reserpine drug targets appeared, and the green 
circle represents tissue-specific KEGG pathway of HCC. The gray side 
indicates that there is a common gene between two pathways, and the more 
number of public genes is, the more rough edge is. 
4 Conclusions 
Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the 
most common type of liver cancer. In this study, we propose an approach 
to identify potential drugs for treatments of HCC, which takes into account 
the special relationships among HCC, liver tissue and KEGG pathways. 
First, we map genes related to HCC to the tissue-specific protein interac-
tion network of liver and get an extended gene set of HCC. Then, based 
on the new tissue-specific gene set of HCC, we extract 12 enriched func-
tional pathways by KEGG pathway enrichment analysis. The 12 KEGG 
pathways are used to calculate the therapeutic score ( TS ) of each drug 
using Kolmogorov–Smirnov statistic. High positive therapeutic scores 
( TS ) indicate the drugs and the HCC pathways have similar expression 
profiles and the drugs might aggravate HCC. On the contrary, negative 
therapeutic scores ( TS ) imply the given drugs and the HCC pathways have 
adverse expression profiles and the drugs could be treatment candidates 
for HCC. That is to say, our method can clearly distinguish therapeutic 
and aggravating drugs for HCC, which make it possible for providing a 
more accurate reference for the treatment of HCC. Furthermore, it is help-
ful in marking some known associations as therapeutic or aggravating be-
tween drugs and diseases in CTD database. Finally, we choose top-six po-
tentially related drugs of HCC for further analysis, including three thera-
peutic drugs and three aggravating drugs. They are validated by analyzing 
their overlaps with drug indications reported in CTD benchmark and Pub-
Med literature. Furthermore, CMap profiles similarity analysis and KEGG 
enrichment analysis are also made on their related genes. These findings 
suggest that our approach is more useful and effective in predicting novel 
therapeutic options for HCC, and it can be easily extended to other dis-
eases. The performance of our proposed method can be further improved 
by integrating more pathway information and tissue data, which will help 
predicting novel drugs for diseases in a more accurate way. 
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